Yuan-Ming Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yuan-Ming Sun has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Xiao-Dong Zhang
Tianjin University
3 shared publications Hao Wang
Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin
2 shared publicationsJiang Yang
Environment, Energy and Natural Resources Center, Department of Environmental Science and Engineering, Fudan University, Shanghai
2 shared publicationsJie Chen
Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin
2 shared publicationsJun-Ying Wang
Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin
2 shared publicationsXiu Shen
Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin
2 shared publications
Latest Publications
- Open Access
- 1 March 2017
- Published by MDPI AG in Applied Sciences
- Vol. 7 (3) , 232
Enhanced Radiation Therapy of Gold Nanoparticles in Liver Cancer
Gold nanoparticles (GNPs) were widely used in X-ray imaging and radiation therapy due to strong photoelectric effects and secondary electrons under high energy irradiation. As liver cancer is one of the most common forms of cancer, the use of GNPs could enhance liver cancer radiotherapy. We synthesized polyethylene glycol (PEG)-coated GNPs of two different sizes by chemical reduction reaction. Blood stability, cellular uptake, cytotoxicity and radiation therapy were investigated. A 3–5 nm red shift of SPR caused by interactions between PEG-coated GNPs and plasma indicated their good stability. Cellular uptake assay showed that PEG-coated GNPs would enhance an appreciable uptake. GNPs preferred to combine with blood proteins, and thus induced the formation of 30–50 nm Au-protein corona. GNPs were endocytosed by cytoplasmic vesicles, localized in intracellular region, and presented concentration dependent cell viability. Clonogenic assay illustrated that the PEG-coated GNPs could sensitize two liver cancer cell lines to irradiation.
- 1 March 2017
- Published by MDPI AG in Applied Sciences
- Vol. 7 (3) , 232
Open AccessEnhanced Radiation Therapy of Gold Nanoparticles in Liver Cancer
Gold nanoparticles (GNPs) were widely used in X-ray imaging and radiation therapy due to strong photoelectric effects and secondary electrons under high energy irradiation. As liver cancer is one of the most common forms of cancer, the use of GNPs could enhance liver cancer radiotherapy. We synthesized polyethylene glycol (PEG)-coated GNPs of two different sizes by chemical reduction reaction. Blood stability, cellular uptake, cytotoxicity and radiation therapy were investigated. A 3–5 nm red shift of SPR caused by interactions between PEG-coated GNPs and plasma indicated their good stability. Cellular uptake assay showed that PEG-coated GNPs would enhance an appreciable uptake. GNPs preferred to combine with blood proteins, and thus induced the formation of 30–50 nm Au-protein corona. GNPs were endocytosed by cytoplasmic vesicles, localized in intracellular region, and presented concentration dependent cell viability. Clonogenic assay illustrated that the PEG-coated GNPs could sensitize two liver cancer cell lines to irradiation.
- Open Access
- 1 July 2016
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 11, 3475-3485
Effects of surface charges of gold nanoclusters on long-term in vivo biodistribution, toxicity, and cancer radiation therapy
Gold nanoclusters (Au NCs) have exhibited great advantages in medical diagnostics and therapies due to their efficient renal clearance and high tumor uptake. The in vivo effects of the surface chemistry of Au NCs are important for the development of both nanobiological interfaces and potential clinical contrast reagents, but these properties are yet to be fully investigated. In this study, we prepared glutathione-protected Au NCs of a similar hydrodynamic size but with three different surface charges: positive, negative, and neutral. Their in vivo biodistribution, excretion, and toxicity were investigated over a 90-day period, and tumor uptake and potential application to radiation therapy were also evaluated. The results showed that the surface charge greatly influenced pharmacokinetics, particularly renal excretion and accumulation in kidney, liver, spleen, and testis. Negatively charged Au NCs displayed lower excretion and increased tumor uptake, indicating a potential for NC-based therapeutics, whereas positively charged clusters caused transient side effects on the peripheral blood system.
- 1 July 2016
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 11, 3475-3485
Open AccessEffects of surface charges of gold nanoclusters on long-term in vivo biodistribution, toxicity, and cancer radiation therapy
Gold nanoclusters (Au NCs) have exhibited great advantages in medical diagnostics and therapies due to their efficient renal clearance and high tumor uptake. The in vivo effects of the surface chemistry of Au NCs are important for the development of both nanobiological interfaces and potential clinical contrast reagents, but these properties are yet to be fully investigated. In this study, we prepared glutathione-protected Au NCs of a similar hydrodynamic size but with three different surface charges: positive, negative, and neutral. Their in vivo biodistribution, excretion, and toxicity were investigated over a 90-day period, and tumor uptake and potential application to radiation therapy were also evaluated. The results showed that the surface charge greatly influenced pharmacokinetics, particularly renal excretion and accumulation in kidney, liver, spleen, and testis. Negatively charged Au NCs displayed lower excretion and increased tumor uptake, indicating a potential for NC-based therapeutics, whereas positively charged clusters caused transient side effects on the peripheral blood system.
- 14 May 2015
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 3 (23) , 4735-4741
Use of epidermal growth factor receptor antibody–gold cluster conjugates with good renal excretion in targeted cancer radiation treatment
Ultra-small gold clusters have been shown to have great potential in biomedical applications; however, it is crucial that the targeting clusters can be rapidly excreted from the body. We prepared epidermal growth factor receptor (EGFR) antibody–gold cluster conjugates with tumour-specific targeting, which also enhanced the effects of therapeutic radiation and had good renal clearance properties. We systematically investigated the effects of these clusters on targeted radiation treatment, renal clearance and toxicity over a period of 25 days in mice. The as-prepared EGFR antibody–gold cluster conjugates showed higher in vitro uptakes than gold clusters alone in treated HeLa cells and resulted in enhanced cancer radiation treatment compared with non-specific gold clusters. The in vivo treatment and improved tumour uptake showed that the EGFR antibody–gold cluster conjugates could result in higher tumour uptake and higher tumour ablation. The EGFR antibody–gold cluster conjugates showed 43% excretion in urine after 24 h, only slightly lower than that of the pure gold clusters (52%). Haematological and biochemical studies showed that the conjugates did not cause liver or kidney toxicity 30 days after injection. Therefore, the use of targeting EGFR antibody–gold cluster conjugates with low toxicities and good renal excretion can enhance radiation treatment and is promising in a number of medical applications.
- 14 May 2015
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 3 (23) , 4735-4741
Use of epidermal growth factor receptor antibody–gold cluster conjugates with good renal excretion in targeted cancer radiation treatment
Ultra-small gold clusters have been shown to have great potential in biomedical applications; however, it is crucial that the targeting clusters can be rapidly excreted from the body. We prepared epidermal growth factor receptor (EGFR) antibody–gold cluster conjugates with tumour-specific targeting, which also enhanced the effects of therapeutic radiation and had good renal clearance properties. We systematically investigated the effects of these clusters on targeted radiation treatment, renal clearance and toxicity over a period of 25 days in mice. The as-prepared EGFR antibody–gold cluster conjugates showed higher in vitro uptakes than gold clusters alone in treated HeLa cells and resulted in enhanced cancer radiation treatment compared with non-specific gold clusters. The in vivo treatment and improved tumour uptake showed that the EGFR antibody–gold cluster conjugates could result in higher tumour uptake and higher tumour ablation. The EGFR antibody–gold cluster conjugates showed 43% excretion in urine after 24 h, only slightly lower than that of the pure gold clusters (52%). Haematological and biochemical studies showed that the conjugates did not cause liver or kidney toxicity 30 days after injection. Therefore, the use of targeting EGFR antibody–gold cluster conjugates with low toxicities and good renal excretion can enhance radiation treatment and is promising in a number of medical applications.
- Open Access
- 29 January 2014
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 15 (2) , 2157-2171
shRNA-Mediated XRCC2 Gene Knockdown Efficiently Sensitizes Colon Tumor Cells to X-ray Irradiation in Vitro and in Vivo
Colon cancer is one of the most common tumors of the digestive tract. Resistance to ionizing radiation (IR) decreased therapeutic efficiency in these patients’ radiotherapy. XRCC2 is the key protein of DNA homologous recombination repair, and its high expression is associated with enhanced resistance to DNA damage induced by IR. Here, we investigated the effect of XRCC2 silencing on colon tumor cells’ growth and sensitivity to X-radiation in vitro and in vivo. Colon tumor cells (T84 cell line) were cultivated in vitro and tumors originated from the cell line were propagated as xenografts in nude mice. The suppression of XRCC2 expression was achieved by using vector-based short hairpin RNA (shRNA) in T84 cells. We found that the knockdown of XRCC2 expression effectively decreased T84 cellular proliferation and colony formation, and led to cell apoptosis and cell cycle arrested in G2/M phase induced by X-radiation in vitro. In addition, tumor xenograft studies suggested that XRCC2 silencing inhibited tumorigenicity after radiation treatment in vivo. Our data suggest that the suppression of XRCC2 expression rendered colon tumor cells more sensitive to radiation therapy in vitro and in vivo, implying XRCC2 as a promising therapeutic target for the treatment of radioresistant human colon cancer.
- 29 January 2014
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 15 (2) , 2157-2171
Open AccessshRNA-Mediated XRCC2 Gene Knockdown Efficiently Sensitizes Colon Tumor Cells to X-ray Irradiation in Vitro and in Vivo
Colon cancer is one of the most common tumors of the digestive tract. Resistance to ionizing radiation (IR) decreased therapeutic efficiency in these patients’ radiotherapy. XRCC2 is the key protein of DNA homologous recombination repair, and its high expression is associated with enhanced resistance to DNA damage induced by IR. Here, we investigated the effect of XRCC2 silencing on colon tumor cells’ growth and sensitivity to X-radiation in vitro and in vivo. Colon tumor cells (T84 cell line) were cultivated in vitro and tumors originated from the cell line were propagated as xenografts in nude mice. The suppression of XRCC2 expression was achieved by using vector-based short hairpin RNA (shRNA) in T84 cells. We found that the knockdown of XRCC2 expression effectively decreased T84 cellular proliferation and colony formation, and led to cell apoptosis and cell cycle arrested in G2/M phase induced by X-radiation in vitro. In addition, tumor xenograft studies suggested that XRCC2 silencing inhibited tumorigenicity after radiation treatment in vivo. Our data suggest that the suppression of XRCC2 expression rendered colon tumor cells more sensitive to radiation therapy in vitro and in vivo, implying XRCC2 as a promising therapeutic target for the treatment of radioresistant human colon cancer.